The literature reports higher PSMA-uptake in high-grade gliomas and metastatic brain tumors than in central-nervous-system lymphoma and radiation necrosis, while there are no data about the differential diagnosis with SFT/HPC because of the rarity of this tumor [25,36,41]. This evidence concerns the gene FOLH1 and glioma.